Evolution of preexisting AICs during treatment with a targeted drug. The status of preexisting AICs at the start of treatment with a targeted drug and their evolution during therapy with ibrutinib (A), idelalisib (B), and venetoclax (C) is depicted. In each group of patients, categorized on the basis of AIC status (ie, resolved, controlled, or active) when the targeted drug was started, the numbers of patients showing different outcomes (ie, resolved, improved, stable, and worsening) are indicated. The tables below each panel report, for each subgroup indicated by symbols, the number of patients receiving additional AIC-directed therapies and the type of concomitant immunosuppressive regimen.